PD-L1 CPS ≥1 is required for pembrolizumab in persistent/recurrent/metastatic cervical ca...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PDL1-CPS-CERVICAL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-05-07 | actionability review required |
| Diseases | DIS-CERVICAL |
| Sources | SRC-ESMO-CERVICAL-2024 SRC-KEYNOTE-826-COLOMBO-2021 SRC-NCCN-CERVICAL-2025 |
Actionability Facts
| Biomarker | BIO-PDL1-CPS |
|---|---|
| Disease | DIS-CERVICAL |
| ESCAT tier | IA |
| Recommended combinations | pembrolizumab + paclitaxel + cisplatin/carboplatin ± bevacizumab (CPS≥1 1L per SRC-NCCN-CERVICAL-2025, SRC-ESMO-CERVICAL-2024, SRC-KEYNOTE-826-COLOMBO-2021) |
| Evidence summary | PD-L1 CPS ≥1 is required for pembrolizumab in persistent/recurrent/metastatic cervical cancer (KEYNOTE-826): pembrolizumab + paclitaxel + cisplatin/carboplatin ± bevacizumab 1L (CPS≥1 mOS 28.6 mo vs 16.5 mo, HR 0.64). FDA-approved 2021. Testing by IHC 22C3 pharmDx. Threshold-gated indication selection performed by the algorithm layer (IND-CERVICAL-METASTATIC-1L-PEMBRO-CHEMO-BEV); this BMA entry surfaces ESCAT context only. |
Notes
Variant_qualifier null — CPS≥1 threshold gating enforced by indication layer. KEYNOTE-826 source stub ingested (SRC-KEYNOTE-826-COLOMBO-2021). ESCAT IA confirmed by FDA approval and NCCN Category 1.
Used By
No reverse references found in the YAML corpus.